Supplementary Material

Table S1. Human biomonitoring studies, in which the ratio between mycotoxin concentration and creatinine content of urine was calculated.

Biomarker	Mean concentration of positive samples [ng mL^{-1}]	Creatinine adjusted concentration [ng mg^{-1} creatinine]	Mean creatinine concentration [mg mL^{-1}]	Creatinine analysis	Matrix effect	Reference
CIT **DH-CIT**	0.03 ± 0.02 0.10 ± 0.10	0.34 ± 0.36 1.02 ± 1.10	1.3 ± 0.9	modified Jaffe method	-	[30]
OTA **OTα** **ZEN** **β-ZEL** **DON** **CIT**	0.37 ± 0.28 9.03 ± 5.25 8.45 ± 5.87 13.30 ± 9.16 43.70 ± 28.39 6.80	0.16 ± 0.11 4.30 ± 1.75 7.00 ± 5.37 9.45 ± 8.25 29.62 ± 26.40 4.50	1.7 ± 0.4	Jaffe's reaction	+	[33]
ZEN **FB1** **α-ZEL** **DON** **β-ZEL** **OTA**	0.529 ± 1.60 1.52 ± 2.17 0.614 ± 1.91 11.3 ± 27.1 0.702 ± 2.95 0.041 ± 0.086	0.204 ± 0.456 0.185 ± 0.236 0.247 ± 0.590 4.94 ± 7.60 0.244 ± 0.820 0.024 ± 0.058	3.4 ± 2.4	Jaffe's reaction	-	[32]
DON **DOM-1** **ZEN** **α-ZEL** **β-ZEL** **FB1** **FB2** **OTA** **NIV**	5.38 ± 12.3 2.32 ± 2.68 0.09 ± 0.07 0.13 ± 0.26 0.10 ± 0.19 0.07 ± 0.06 0.06 ± 0.12 0.90 ± 0.50 0.13 ± 0.14	7.02 ± 24.4 1.56 ± 1.26 0.14 ± 0.13 0.19 ± 0.26 0.13 ± 0.18 0.13 ± 0.26 0.16 ± 0.51 1.43 ± 1.74 0.12 ± 0.07	0.8 ± 0.3	Test™ Creatinine Enzymatic	-	[41]
AFM1 **FB1** **OTA** **DON-15-GlcA** **DON-3-GlcA** **ZEN** **ZEN-14-GlcA** **NIV**	0.05 0.63 0.08 5.49 3.93 0.22 0.81 2.61	0.04 0.33 0.07 5.72 3.88 0.21 0.765 2.87	1.2 ± 0.3	LC-MS/MS	-	[39]
OTA **OTα**	0.21 ± 0.31 1.33 ± 2.63	0.17 ± 0.22 1.01 ± 1.94	1.3 ± 0.1	modified Jaffe method	-	[34]
DON	18.8 ± 3.5	17.5 ± 2.7	1.1	Jaffe's reaction	-	[35]
DON-3-GlcA **DON-15-GlcA** **AFM1**	4.3 8.1 0.33	2.4 4.8 0.31	1.5 ± 0.4	LC-MS/MS	-	[40]

ZEN	0.10 ± 0.05	0.09 ± 0.05		modified		
α-ZEL	0.16 ± 0.07	0.16 ± 0.13	1.4 ± 0.9	Jaffe	-	[36]
β-ZEL	0.05 ± 0.04	0.04 ± 0.05		method		